JP2012532194A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532194A5
JP2012532194A5 JP2012519612A JP2012519612A JP2012532194A5 JP 2012532194 A5 JP2012532194 A5 JP 2012532194A5 JP 2012519612 A JP2012519612 A JP 2012519612A JP 2012519612 A JP2012519612 A JP 2012519612A JP 2012532194 A5 JP2012532194 A5 JP 2012532194A5
Authority
JP
Japan
Prior art keywords
acid
formulation
layer
pharmaceutically acceptable
tpr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012519612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532194A (ja
Filing date
Publication date
Priority claimed from US12/688,493 external-priority patent/US20110003005A1/en
Application filed filed Critical
Publication of JP2012532194A publication Critical patent/JP2012532194A/ja
Publication of JP2012532194A5 publication Critical patent/JP2012532194A5/ja
Pending legal-status Critical Current

Links

JP2012519612A 2009-07-06 2010-07-02 持続放出オンダンセトロン組成物を用いたｐｄｎｖ及びｐｏｎｖの処置方法 Pending JP2012532194A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22321809P 2009-07-06 2009-07-06
US61/223,218 2009-07-06
US12/688,493 US20110003005A1 (en) 2009-07-06 2010-01-15 Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US12/688,493 2010-01-15
PCT/US2010/040868 WO2011005671A1 (en) 2009-07-06 2010-07-02 Methods of treating pdnv and ponv with extended release ondansetron compositions

Publications (2)

Publication Number Publication Date
JP2012532194A JP2012532194A (ja) 2012-12-13
JP2012532194A5 true JP2012532194A5 (https=) 2013-08-22

Family

ID=43412803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519612A Pending JP2012532194A (ja) 2009-07-06 2010-07-02 持続放出オンダンセトロン組成物を用いたｐｄｎｖ及びｐｏｎｖの処置方法

Country Status (8)

Country Link
US (1) US20110003005A1 (https=)
EP (1) EP2451276A4 (https=)
JP (1) JP2012532194A (https=)
AR (1) AR077394A1 (https=)
BR (1) BR112012000095A2 (https=)
TW (1) TW201105657A (https=)
UY (1) UY32767A (https=)
WO (1) WO2011005671A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012013011A2 (pt) * 2009-11-30 2015-09-08 Aptalis Pharmatech Inc odt; composição de odt; método para a preparação de um tablete de odt multiparticulado, método para tratar ou prevenir náusea e vômito pós operatória ou náusea e vômito pós- alta por até 24 horas após a dosagem, método para tratar pu prevenir náusea por até 24 horas após a dosagem e método para tratar ou prevenir náusea e vômito associados a radioterapia em pacientes que recebem ou irradiação de corpo total, dose alta única ao abdômen, ou frações diárias ao abdômen por até 24 horas após a dosagem
JP6250394B2 (ja) 2010-08-19 2017-12-20 バック・インスティテュート・フォー・リサーチ・オン・エイジング 軽度の認知障害（ｍｃｉ）および関連障害の処置方法
EP2814491A4 (en) * 2012-02-18 2015-08-26 Buck Inst For Res On Aging FORMULATIONS AND METHODS FOR TREATING OR PROPHYLAXIS OF PRE-MCI AND / OR PRE-ALZHEIMER ILLNESSES
WO2014004126A1 (en) * 2012-06-26 2014-01-03 Fleming C Andrew Treating postoperative nausea and vomiting
US9636305B2 (en) * 2013-03-14 2017-05-02 Redhill Biopharma Ltd. Antiemetic extended release solid dosage forms
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
SG11201607511WA (en) * 2014-03-11 2016-10-28 Redhill Biopharma Ltd Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
IE48715B1 (en) * 1978-12-22 1985-05-01 Elan Corp Plc New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4826688A (en) * 1985-11-13 1989-05-02 501 Elan Corporation PLC. Controlled absorption pharmaceutical formulation
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
EP0585355B1 (en) * 1991-05-20 1995-03-22 Marion Laboratories, Inc. Multi-layered controlled release formulation
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
CA2322315C (en) * 1998-03-06 2008-09-16 Eurand International S.P.A. Fast disintegrating tablets
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
EP1126826B3 (en) * 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6936275B2 (en) * 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
CN1404388A (zh) * 2000-01-20 2003-03-19 德尔西斯药品公司 多级药物剂型
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
PT1405621E (pt) * 2001-06-20 2011-05-31 Takeda Pharmaceutical Processo de prepara??o de comprimidos
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US20040019096A1 (en) * 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
CA2579767A1 (en) * 2004-04-30 2005-11-10 Astellas Pharma Inc. Oral pharmaceutical composition in timed-release particle form and fast-disintegrating tablets containing this composition
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
CA2635313C (en) * 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
RU2428176C2 (ru) * 2006-01-27 2011-09-10 Юранд, Инк. Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты
CN103211779B (zh) * 2006-01-27 2016-03-16 阿代尔制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
CN101573106B (zh) * 2006-10-24 2013-07-24 赫尔辛医疗股份公司 具有改进的稳定性和生物利用度的含帕洛司琼盐酸盐的软胶囊剂
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids

Similar Documents

Publication Publication Date Title
JP2012532194A5 (https=)
KR101752014B1 (ko) 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
JP2013199488A5 (https=)
TWI440480B (zh) 包含弱鹼性藥物及有機酸之藥物遞送系統
JP2013512250A5 (https=)
JP5878022B2 (ja) 抗コリン薬を具える放出制御組成物
JP2012532194A (ja) 持続放出オンダンセトロン組成物を用いたｐｄｎｖ及びｐｏｎｖの処置方法
KR102408645B1 (ko) 안정성이 증가된 에스오메프라졸 함유 이중코팅정 조성물 및 이의 제조방법
MX2007010889A (es) Formulaciones farmaceuticas gastrorresistentes que contienen rifaximina.
JP2012518655A5 (https=)
JP2007119479A5 (https=)
JP2011509295A5 (https=)
US20110135724A1 (en) Ondansetron Orally Disintegrating Tablet Compositions for Prevention of Nausea and Vomiting
US11564888B2 (en) Extended release compositions comprising trihexyphenidyl
CN105392486A (zh) 口腔崩解片
CA2584419A1 (en) New modified release tablet formulations for proton pump inhibitors
EP4007568A1 (en) Pharmaceutical composition comprising dabigatran etexilate
CN100393304C (zh) 一种包含酸不稳定药物的微细颗粒及其制剂
AU2007311493B2 (en) Multiple unit tablet compositions of benzimidazole compounds
JP5919173B2 (ja) 徐放性塩酸アンブロキソール口腔内崩壊錠
JP2019507181A5 (https=)
CN107249569A (zh) 一种包含含有盐酸坦索罗辛的缓释颗粒的口服药物制剂
JP2013536832A (ja) ミルナシプランの制御放出医薬組成物
WO2017145146A1 (en) Compositions comprising proton pump inhibitors
JP2018184360A (ja) 経口投与用の腸溶性徐放性製剤